Posted On: 03/29/2013 5:26:06 PM
Post# of 63824
Business Wire Health stories.
-
-
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Preferred Stock Shareholders
03/29/2013 - 02:44 PM
-
Northwestern Mutual – The South Florida Group and Cheeriodicals Use Team Building Activity to Spread Cheer to Joe DiMaggio Children’s Hospital
03/29/2013 - 01:14 PM
-
Covidien Awarded $176.5 Million Verdict in Patent Litigation against Ethicon Endo-Surgery
03/29/2013 - 12:54 PM
-
Innovatix to Exhibit at Inaugural National Association of Specialty Pharmacy Conference
03/29/2013 - 12:48 PM
-
Retina Institute Japan und Dainippon Sumitomo Pharma gründen Kapitalallianz zur Entwicklung der mit dem Nobel-Preis ausgezeichneten iPS-Zelltechnologie
03/29/2013 - 12:30 PM
-
Retina Institute Japan et Dainippon Sumitomo Pharma concluent une alliance cruciale pour le développement de la technologie cellulaire iPS, détentrice du Prix Nobel
03/29/2013 - 12:30 PM
-
Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer
03/29/2013 - 11:51 AM
-
Samenvatting: Aptalis Pharma SAS kiest voor Mobile Intelligence CRM en OneKey van Cegedim Relationship Management
03/29/2013 - 11:26 AM
-
KOHJIN Life Sciences and Kyoto Prefectural University presented the findings on the Identification of Glutathione in Human Blood after Oral Administration at the ISNFF Academic Meeting.
03/29/2013 - 11:00 AM
-
-
-
-
Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Skin Breakdown Prevention Products
03/29/2013 - 09:00 AM
-
Affordable Care Act Requires Americans Take a More Active Role in Health Care Decisions
03/29/2013 - 08:00 AM
-
Cytori to Webcast at the Future Leaders in the Biotech Industry Conference on April 5, 2013
03/29/2013 - 08:00 AM
-
FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy
03/29/2013 - 08:00 AM
-
Flunixin Meglumine (CAS 42461-84-7) Market Discussed in Discounted BAC Report Recently Published at MarketPublishers.com
03/29/2013 - 07:29 AM
-
-
Dipotassium Glycyrrhizinate (CAS 68797-35-3) Market Studied in Discounted BAC Report Now Available at MarketPublishers.com
03/29/2013 - 07:08 AM
-
Sucampo Pharmaceuticals to Present at 20th Annual Future Leaders in the Biotech Industry Conference
03/29/2013 - 06:45 AM
-
-
(0)
(0)
